What is the official website of EVA pharma ?

The official website of EVA pharma is http://www.evapharma.com.

What is EVA pharma's cybersecurity risk score?

EVA pharma has an AI-generated cybersecurity risk score of 780 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has EVA pharma experienced?

According to Rankiteo, EVA pharma currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has EVA pharma been affected by any supply chain cyber incidents ?

According to Rankiteo, EVA pharma has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does EVA pharma have SOC 2 Type 1 certification ?

According to Rankiteo, EVA pharma is not certified under SOC 2 Type 1.

Does EVA pharma have SOC 2 Type 2 certification ?

According to Rankiteo, EVA pharma does not hold a SOC 2 Type 2 certification.

Does EVA pharma comply with GDPR ?

According to Rankiteo, EVA pharma is not listed as GDPR compliant.

Does EVA pharma have PCI DSS certification ?

According to Rankiteo, EVA pharma does not currently maintain PCI DSS compliance.

Does EVA pharma comply with HIPAA ?

According to Rankiteo, EVA pharma is not compliant with HIPAA regulations.

Does EVA pharma have ISO 27001 certification ?

According to Rankiteo,EVA pharma is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does EVA pharma operate in ?

EVA pharma operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does EVA pharma have ?

EVA pharma employs approximately 5,679 people worldwide.

Does EVA pharma own any subsidiaries ?

EVA pharma presently has no subsidiaries across any sectors.

How many LinkedIn followers does EVA pharma have ?

EVA pharma's official LinkedIn profile has approximately 517,176 followers.

What is the NAICS classification code for EVA pharma ?

EVA pharma is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does EVA pharma have a Crunchbase profile ?

No, EVA pharma does not have a profile on Crunchbase.

Does EVA pharma have a LinkedIn profile ?

Yes, EVA pharma maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/eva-pharma.

How many cybersecurity incidents has EVA pharma experienced ?

As of September 6, 2026, Rankiteo reports that EVA pharma has not experienced any cybersecurity incidents.

How many peer or competitor companies does EVA pharma have ?

EVA pharma has an estimated 5,755 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

EVA pharma

Boost Score +25 with badge (5 left)

780

/1000

Fair

805

/1000

Good

EVA pharma Vendor Cyber Rating & Cyber Score

evapharma.com

Add Your Compliance Badge

EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biological products. With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies. Guided by a relentless drive to ensure sustainable access to pressing

EVA pharma A.I CyberSecurity Scoring

Scoring History

EVA pharma

EVA pharma CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

EVA pharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for EVA pharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for EVA pharma in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for EVA pharma in 2026.

Incident Types EVA pharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for EVA pharma in 2026.

Incident History - EVA pharma (X = Date, Y = Severity)

Loading…

SUBSIDIARY

EVA pharma Subsidiaries

Parent Company

EVA pharma

Pharmaceutical Manufacturing

Website: http://www.evapharma.com

Company Size: 5,679

No subsidiary data available for this company.

Loading…

EVA pharma Similar Companies

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Loading…

NEWS

EVA pharma CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

June 27, 2025 07:00 AM

Porton Advanced and EVA Pharma collaborate for CAR T-cell therapies

Porton Advanced Solutions and EVA Pharma have signed a memorandum of understanding (MoU) to enhance the development and manufacturing...

Read Article

June 26, 2025 07:00 AM

EVA Pharma and BioPharma Town - Qiantang District, Hangzhou Sign a Strategic Cooperation Agreement

EVA Pharma Deepens Its Roots in China's Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou OfficeHANGZHOU,...

Read Article

September 04, 2024 07:00 AM

Eli Lilly signs manufacturing deal for rheumatoid arthritis drug in Africa

Eli Lilly will license the manufacturing know-how for its rheumatoid arthritis treatment to Egypt's Eva Pharma, the companies said on...

Read Article

December 17, 2023 08:00 AM

EVA Pharma announces groundbreaking of its research & manufacturing complex in Sudair

With investments exceeding SAR 450 million, EVA Pharma is moving steadfastly with the launch of a 50+ thousands sqm research & manufacturing...

Read Article

June 26, 2023 07:00 AM

FTI Consulting Expands Cybersecurity Practice into Hong Kong with Appointment of Eva Kwok

WASHINGTON, June 26, 2023 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Eva Kwok as a Senior...

Read Article

May 10, 2021 07:00 AM

Egypt's Eva Pharma to export COVID-19 drug remdesivir to India

Egypt's Eva Pharma on Monday signed an agreement to provide India with 300000 doses of remdesivir, used in the treatment of COVID-19,...

Read Article

June 25, 2020 07:00 AM

Egypt's Eva Pharma begins producing COVID-19 drug Remdesivir

Egypt's Eva Pharma said on Thursday it had begun producing Remdesivir and Favipiravir, two drugs used in the treatment of patients with...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-86150

SUMMARY

A security vulnerability has been detected in Tenda CP3 27.5.57.101. Impacted is an unknown function of the file custom-x/softap/hostapd. Such manipulation of the argument wpa_passphrase leads to hard-coded credentials. The attack can be launched remotely. The exploit has been disclosed publicly and may be used.

Published

Date2026-09-05

Updated

Date2026-09-05

RISK INFORMATION (Score: 4.1)

cvss2

Base Score: 3.3

Complexity: LOW

AV:N/AC:L/Au:M/C:P/I:N/A:N

cvss3

Base Score: 4.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:L/I:N/A:N

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:L/VI:N/VA:N/SC:L/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.3

REFERENCES

CVE-2026-86149

SUMMARY

A weakness has been identified in Tenda CP3 27.5.57.101. This issue affects some unknown processing of the file Net/NetCheckPing.cpp. This manipulation of the argument interface_name/host causes os command injection. The attack can be initiated remotely.

Published

Date2026-09-05

Updated

Date2026-09-05

RISK INFORMATION (Score: 9.1)

cvss2

Base Score: 8.3

Complexity: LOW

AV:N/AC:L/Au:M/C:C/I:C/A:C

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 9.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

2.3

REFERENCES

CVE-2026-86148

SUMMARY

A security flaw has been discovered in Tenda CP3 27.5.57.101. This vulnerability affects the function SystemAsh of the file Apis/system.c of the component Kylin. The manipulation of the argument AlarmVoiceURL results in os command injection. It is possible to launch the attack remotely.

Published

Date2026-09-05

Updated

Date2026-09-05

RISK INFORMATION (Score: 9.1)

cvss2

Base Score: 8.3

Complexity: LOW

AV:N/AC:L/Au:M/C:C/I:C/A:C

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 9.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

2.3

REFERENCES

CVE-2026-86206

SUMMARY

A vulnerability in the N-central internal API access control filter allows unauthorised access to internal APIs. This is fixed in N-central 2026.3 HF3 and 2026.4

Published

Date2026-09-05

Updated

Date2026-09-05

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-86060

SUMMARY

RouterOS contains an argument-handling flaw in the SSH login path involving usernames that begin with a prohibited character, allowing for the trusted RouterOS policy mask to be changed, leading to privilege escalation. Exploitation requires an unauthenticated SSH session to reach the RouterOS login helper.This issue was fixed in versions: 6.49.21 (Long-term), 7.23.4 (Long-term) and 7.24.2 (Stable)

Published

Date2026-09-05

Updated

Date2026-09-05

RISK INFORMATION (Score: )

cvss4

Base Score: 9.2

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…